We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




AACC Releases Guidelines on Point-of-Care Testing for Non-Laboratorians

By LabMedica International staff writers
Posted on 14 Sep 2022

Point-of-care testing (POCT), or near-patient testing, is diagnostic testing conducted close to the patient, often by clinical personnel outside of the laboratory. More...

POCT is regularly performed by personnel without a laboratory science degree or credentialing in laboratory medicine. Now, a new guidance document is available for non-laboratorians who are involved in setting up a process or physical space designed to provide testing at or near where patient care is provided.

The guide released by the American Association for Clinical Chemistry (AACC, Washington, DC, USA) presents the challenges to consider when selecting and implementing diagnostic testing. It provides an overview of POCT, including a discussion of the cost-benefit analysis of implementing POCT and the use of POCT in various healthcare settings. The AACC guide presents the challenges to consider when selecting and implementing POCT. It also offers tools to address and manage those challenges and offers solutions to overcome barriers faced in various settings to ensure quality test results that are reliable for patient care.

The AACC guide includes addenda, including glossaries, templates, and forms, to serve as tools in the implementation of POCT. These are for reference use only; individual POCT laboratories may have unique needs. The guide is not meant to be an all-inclusive ‘how to’ set up a POCT laboratory and is to be used as supportive instruction and education to implement good laboratory practices, according to the AACC. The guide is most helpful when used in conjunction with all information provided by the test manufacturer, including the Manufacturer’s Instructions for Use (MIFU) for testing materials, products, and devices that one has selected to provide laboratory testing services to patients.

Related Links:
AACC 


New
Gold Member
Pre- Eclampsia Control
Acusera Pre-Eclampsia Control
Online QC Software
Acusera 24•7
Pipette Calibration System
Artel PCS®
Chromogenic Culture System
InTray™ COLOREX™ ECC
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Capillary testing on the Atellica analyzers supports the most common laboratory testing needs (Photo courtesy of Siemens Healthineers)

Siemens Adds CE-Marked Capillary Claims for 24 Assays on Atellica Analyzers

Venous blood draws can be challenging in patients with difficult veins, needle phobia, or limited blood volume, and they can slow collection in busy services. Core laboratories also face pressure to expand... Read more

Immunology

view channel
Image: Graphical Abstract (Morgane Fournier et al., Cell (2026). DOI: 10.1016/j.cell.2026.04.013)

Study Reveals Immune Mechanism Driving Severe COVID-19 Progression

Severe COVID-19 has highlighted gaps in understanding of early antiviral responses, particularly why some patients deteriorate despite timely care. Type I interferons are central to host defense, yet their... Read more

Pathology

view channel
Image: Agilent’s PD-L1 IHC 22C3 pharmDx has received EU certification as a companion diagnostic to identify PD-L1–positive ovarian, fallopian tube, or primary peritoneal carcinoma patients eligible for KEYTRUDA (Photo courtesy of Agilent)

PD-L1 Assay Guides Pembrolizumab Eligibility in Ovarian, Fallopian Tube, and Peritoneal Cancers

Agilent Technologies’ PD-L1 IHC 22C3 pharmDx (Code SK006) has received European Union certification as a companion diagnostic to aid in identifying patients with epithelial ovarian, fallopian tube, or... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.